Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 12/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 12/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 12/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 12/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383623 | 0.93 | TSHR (0.43) | HTR1AADRA1DADRA1AADRA1BL3MBTL1 | |
| SCHEMBL1382684 | 0.91 | ALDH1A1 (0.48) | ALDH1A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL13617358 | 0.89 | TSHR (0.38) | ALDH1A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1380766 | 0.88 | BRD4 (0.38) | ALDH1A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL2829817 | 0.86 | TSHR (0.35) | ALDH1A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1381520 | 0.84 | ALDH1A1 (0.43) | ALDH1A1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL2832891 | 0.84 | DRD2 (0.41) | ALDH1A1TSHRPOLBKDM4E | |
| SCHEMBL1382723 | 0.83 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBKDM4E | |
| SCHEMBL2830140 | 0.82 | L3MBTL1 (0.42) | ALDH1A1HTR1AL3MBTL1TSHRKDM4E | |
| SCHEMBL13617548 | 0.81 | CYP1A2 (0.38) | ALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781441-B2 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781441-B2 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781441-B2 | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1888538-B1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-1888538-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HOFFMANN-LA ROCHE INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006117305-A1 | (3,4-DIHYDRO-QUINAZOLIN-2-YL)-(2-ARYLOXY-ETHYL)-AMINES HAVING AN ACTIVITY ON THE 5-HT RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252779-A1 | (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine | HTR5A, NPY5R, HTR3A | ALDH1A1 780/4885HTR1A 4/4885ADRA1D 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.